• Explore /
  • Poster
  • / A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.

A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.

Abstract Poster

Authors

null

Orazio Caffo

Santa Chiara Hospital, Trento, Italy

Orazio Caffo , Erica Palesandro , Franco Nole , Donatello Gasparro , Claudia Mucciarini , Michele Aieta , Roberto Iacovelli , Ugo De Giorgi , Sabrina Rossetti , Marco Maruzzo , Lucia Fratino , Cosimo Sacco , Maurizio Nicodemo , Monica Giordano , Donata Sartori , Daniela Scapoli , Elena Verri , Antonello Veccia , Giovanni L. Pappagallo , Massimo Aglietta

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02453009

Citation

J Clin Oncol 37, 2019 (suppl; abstr 5050)

DOI

10.1200/JCO.2019.37.15_suppl.5050

Abstract #

5050

Poster Bd #

162

Abstract Disclosures

Similar Posters

First Author: Orazio Caffo

First Author: Sumit Kumar Subudhi

First Author: Johann S. De Bono

First Author: Emily Nash Smyth